10-Q: BioNexus Gene Lab Corp. Reports Q3 2024 Results Amidst Internal Reviews and Nasdaq Delisting Concerns

BioNexus Gene Lab Corp. reports a net loss for Q3 2024, alongside ongoing internal investigations and a Nasdaq delisting notice.

Summary

• BioNexus Gene Lab Corp. reported a net loss of $1.345 million for the third quarter of 2024, compared to a net loss of $2.609 million in the same period of 2023.
• Revenue for the quarter was $2.630 million, a slight increase from $2.553 million in Q3 2023.
• The company's operating expenses decreased to $2.129 million from $3.082 million year-over-year.
• For the nine months ended September 30, 2024, the company's net loss was $1.250 million, compared to a net loss of $2.937 million for the same period in 2023.
• The company's revenue for the nine months was $6.986 million, a decrease from $7.497 million in the same period of 2023.
• The company is facing a potential delisting from Nasdaq due to its failure to maintain a minimum bid price of $1.00 per share.
• Internal investigations are underway regarding certain transactions at the Chemrex subsidiary, including a property sale, related-party transactions, and unauthorized director remuneration increases.

Sentiment

Score: 3

Explanation: The document reveals significant financial losses, internal control issues, and a potential Nasdaq delisting, indicating a negative outlook for the company. While there are some improvements in loss reduction, the overall picture is concerning.

Positives

• The company's net loss decreased significantly in both Q3 and the nine-month period compared to the previous year.
• Operating expenses were reduced by 30.9% in Q3 2024 and 20.1% for the nine-month period.
• Other income increased substantially due to dividends, gains on equity investments, and recovery of doubtful debts.
• The company has taken steps to enhance internal controls and governance procedures.

Negatives

• The company experienced a slight decrease in revenue for the nine-month period compared to the previous year.
• The company received a delisting notification from Nasdaq due to its failure to maintain a minimum bid price.
• Internal investigations are underway regarding several concerning transactions at the Chemrex subsidiary.
• There were unauthorized increases in director remuneration at Chemrex.
• The company's working capital decreased from $6.415 million to $5.635 million.

Risks

• The company faces the risk of being delisted from Nasdaq if it cannot regain compliance with listing rules.
• Ongoing internal investigations at Chemrex could lead to further financial adjustments and reputational damage.
• The company's liquidity could be negatively impacted by increased administrative and marketing expenses.
• The company's revenue is subject to fluctuations in purchasing conditions and competition.
• The company is exposed to foreign exchange rate fluctuations.

Future Outlook

The company believes that cash flow from operations will be sufficient to sustain its current level of operations for at least the next 12 months. The company intends to present a compliance plan at the Nasdaq hearing, including potential corrective actions such as a reverse stock split, to regain compliance with Nasdaq's listing standards.

Management Comments

• Management concluded that the company's disclosure controls and procedures were effective in recording, processing, summarizing, and reporting information.
• Management considers its internal control over financial reporting required further improvement.
• Management is implementing strengthened review and authorization procedures to address potential control gaps at Chemrex.

Industry Context

The company operates in the biochemical industry, with a focus on functional genomics for early disease detection and industrial chemical distribution. The results of operations for Chemrex were adversely impacted during fiscal year 2023 and the slow recovery into 2024 as the businesses of Chemrex customers especially manufacturers continue to suffer from the lingering impact of Covid and supply chain shocks to the global economy.

Comparison to Industry Standards

• The company's revenue growth is below the industry average for the biochemical sector, which has seen a rebound in demand post-pandemic.
• The company's operating expenses are higher than industry benchmarks, particularly in the area of general and administrative costs.
• The company's net loss is significantly higher than the industry average, indicating potential issues with profitability and cost management.
• The company's internal control weaknesses are a concern, as most public companies in the sector have robust internal control frameworks.
• The company's reliance on a few major customers and suppliers is a risk, as it makes them vulnerable to changes in their business conditions.
• The company's Nasdaq delisting notice is a significant negative, as most companies in the sector are able to maintain their listing status.

Management Changes

Corporate Governance

Legal Proceedings

• There are presently no pending legal proceedings to which the Company or any of its property is subject.

Related Party Transactions

• Chemrex purchased materials totaling MYR 789,696 (approximately USD $170,460) from Honkuk Material Sdn. Bhd., a company owned by certain directors of Chemrex.
• Chemrex made payments totaling MYR 200,000 (approximately USD $43,171) to Mr. Wong Kim Hai, a director of Chemrex, as part of his compensation for services.

Stakeholder Impact

• Shareholders are negatively impacted by the potential delisting from Nasdaq and the ongoing internal investigations.
• Employees may be affected by the restructuring and changes in management.
• Customers and suppliers may be impacted by the uncertainty surrounding the company's financial stability and internal control issues.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company will present a compliance plan at the Nasdaq hearing to appeal the delisting determination.
• The company will continue its internal investigations into the transactions at Chemrex.
• The company will implement strengthened review and authorization procedures to address potential control gaps.
• The company will work with Maxim Group LLC to explore potential merger and acquisition opportunities and financing options.

Key Dates

Keywords

BioNexus Gene Lab Corp, BGLC, Chemrex, MRNA Scientific, Nasdaq, delisting, internal controls, financial results, quarterly report, related party transactions, director remuneration, operating expenses, revenue, net loss, audit committee, investigation